AASLD Liver meeting 2024

Nov 15 - Nov 19, 2024 | San Diago, CA

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Factors Associated With Type of First-Line Treatment Received for Unresectable Hepatocellular Carcinoma in the Era of Immunotherapy: Evidence From US Community Oncology Practices

Authors Cheng S, To TM, Schuldt R, Tan A

Published date17 November, 2024

Atezolizumab-bevacizumab is the current standard of care for first-line treatment of unresectable HCC. This poster reports on the characterization of patients in a contemporaneous cohort who initiated first-line therapy following the approval of atezolizumab-bevacizumab and identifies factors associated with the use of tyrosine kinase inhibitors relative to atezolizumab-bevacizumab in the US community oncology setting.

of 0
Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

Not a healthcare professional? Browse:

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.